Shanghai's Abbisko out-licenses EGFR candidate in potentially nine-figure deal
A Shanghai-based biotech is handing off rights to one of its candidates to another Shanghai company.
Qiming-backed Abbisko — headed by Eli Lilly and Novartis veteran Yao-Chang Xu — said Wednesday that it would be out-licensing its candidate ABK3376 to Allist Pharmaceuticals. The small molecule is a preclinical, brain-penetrant EGFR inhibitor which can inhibit different mutations such as L858R activating mutation or the exon 19 deletion mutation, Abbisko said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.